LEVOPHED Drug Patent Profile
✉ Email this page to a colleague
When do Levophed patents expire, and what generic alternatives are available?
Levophed is a drug marketed by Hospira and is included in one NDA.
The generic ingredient in LEVOPHED is norepinephrine bitartrate. There are five drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Levophed
A generic version of LEVOPHED was approved as norepinephrine bitartrate by MEITHEAL on March 3rd, 2003.
Summary for LEVOPHED
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 77 |
Clinical Trials: | 12 |
Patent Applications: | 3,763 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LEVOPHED |
What excipients (inactive ingredients) are in LEVOPHED? | LEVOPHED excipients list |
DailyMed Link: | LEVOPHED at DailyMed |
Recent Clinical Trials for LEVOPHED
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Wright State University | Phase 3 |
Kasr El Aini Hospital | Phase 4 |
Yale University | Early Phase 1 |
Pharmacology for LEVOPHED
Drug Class | Catecholamine |
Anatomical Therapeutic Chemical (ATC) Classes for LEVOPHED
US Patents and Regulatory Information for LEVOPHED
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospira | LEVOPHED | norepinephrine bitartrate | INJECTABLE;INJECTION | 007513-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |